Insulet Corporation (NASDAQ:PODD) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Insulet Corporation (NASDAQ:PODD) have earned an average rating of “Moderate Buy” from the twenty-four research firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $379.10.

Several research analysts have recently commented on the company. UBS Group restated a “buy” rating on shares of Insulet in a research report on Thursday, December 18th. Truist Financial cut their price target on shares of Insulet from $412.00 to $390.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Wells Fargo & Company raised their price objective on shares of Insulet from $350.00 to $360.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Evercore ISI assumed coverage on shares of Insulet in a report on Tuesday, December 16th. They set an “outperform” rating and a $370.00 target price on the stock. Finally, Wolfe Research raised their price target on shares of Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research report on Friday, November 7th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. True Wealth Design LLC boosted its stake in shares of Insulet by 288.0% in the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 72 shares during the period. Golden State Wealth Management LLC increased its position in shares of Insulet by 202.9% in the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 69 shares during the last quarter. Trust Co. of Toledo NA OH acquired a new stake in shares of Insulet in the 2nd quarter valued at $35,000. Whittier Trust Co. of Nevada Inc. lifted its position in shares of Insulet by 48.9% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 43 shares during the last quarter. Finally, Quent Capital LLC purchased a new position in Insulet in the third quarter valued at $49,000.

Insulet Trading Down 1.7%

Shares of PODD stock opened at $280.00 on Friday. Insulet has a 1-year low of $230.05 and a 1-year high of $354.88. The firm has a market cap of $19.70 billion, a PE ratio of 81.16, a price-to-earnings-growth ratio of 1.59 and a beta of 1.40. The company has a 50-day moving average of $299.71 and a two-hundred day moving average of $310.35. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping the consensus estimate of $1.13 by $0.11. The firm had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. Insulet had a net margin of 9.76% and a return on equity of 24.36%. The business’s revenue for the quarter was up 29.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.08 EPS. On average, analysts predict that Insulet will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.